Top

Published in:

01-07-2013 | Translational Research and Biomarkers

Common Variants in IGF1 Pathway Genes and Clinical Outcomes After Radical Prostatectomy

Authors: Chi-Fen Chang, PhD, Jiunn-Bey Pao, MS, Chia-Cheng Yu, MD, Chao-Yuan Huang, MD, PhD, Shu-Pin Huang, MD, PhD, Ying-Pi Yang, MS, Chun-Nung Huang, MD, PhD, Ta-Yuan Chang, PhD, Bang-Jau You, PhD, Hong-Zin Lee, PhD, Tzyh-Chyuan Hour, PhD, Bo-Ying Bao, PhD

Published in: Annals of Surgical Oncology | Issue 7/2013

Abstract

Background

Insulin-like growth factor-1 (IGF1) pathway plays a critical role in malignant transformation, and epidemiology studies have also shown that single nucleotide polymorphisms (SNPs) in IGF1 pathway genes are associated with prostate cancer risk. However, the clinical significance of these SNPs on prostate cancer aggressiveness and prognosis after radical prostatectomy (RP) has not been determined.

Methods

We evaluated the associations of 4 common SNPs in IGF1 and IGF1R with age at diagnosis, preoperative prostate-specific antigen (PSA) level, pathologic Gleason score, pathologic stage, surgical margin, lymph node metastasis, and PSA recurrence in a cohort of 320 localized prostate cancer patients receiving RP. The prognostic significance on time to PSA recurrence was also assessed by Cox proportional hazards model.

Results

IGF1 rs2946834 alleles/genotypes and an IGF1 specific haplotype AT, containing the minor allele of rs2946834, were associated (P ≤ 0.028) with a 1.49- to 2.22-fold higher risk of having advanced-stage prostate cancer. In addition, a genetic interaction profile consisting of IGF1 rs2946834 and IGF1R rs2016347 was significantly associated with PSA recurrence (P = 0.033).

Conclusions

Our study is the first to evaluate the impact of SNPs in IGF1 pathway genes on PSA recurrence. A genetic interaction between IGF1 rs2946834 and IGF1R rs2016347 might be a predictor of outcomes following RP.

Available only for authorised users

Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.PubMedCrossRef

Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 1993;90:11217–21.PubMedCrossRef

Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11:530–42.PubMedCrossRef

Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620–5.PubMedCrossRef

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008;149:461–71, W83–8.PubMedCrossRef

Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. J Endocrinol Invest. 1999;22:48–57.PubMed

Gu F, Schumacher FR, Canzian F, Allen NE, Albanes D, Berg CD, et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:2877–87.PubMedCrossRef

Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010;19:3089–101.PubMedCrossRef

Bao BY, Lin VC, Huang SH, Pao JB, Chang TY, Lu TL, et al. Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer. Ann Surg Oncol. 2010;17:1675–81.PubMedCrossRef

10.

Bao BY, Pao JB, Lin VC, Huang CN, Chang TY, Lan YH, et al. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta. 2010;411:1232–7.PubMedCrossRef

11.

Huang SP, Huang LC, Ting WC, Chen LM, Chang TY, Lu TL, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009;18:3068–74.PubMedCrossRef

12.

Huang SP, Ting WC, Chen LM, Huang LC, Liu CC, Chen CW, et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol. 2010;17:312–22.PubMedCrossRef

13.

Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61:365–9.PubMedCrossRef

14.

Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet. 2006;15:1–10.PubMedCrossRef

15.

Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev. 2008;17:880–8.PubMedCrossRef

16.

Lonn S, Rothman N, Shapiro WR, Fine HA, Selker RG, Black PM, et al. Genetic variation in insulin-like growth factors and brain tumor risk. Neuro Oncol. 2008;10:553–9.PubMedCrossRef

17.

Verheus M, McKay JD, Kaaks R, Canzian F, Biessy C, Johansson M, et al. Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density. Breast Cancer Res Treat. 2008;112:109–22.PubMedCrossRef

18.

Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene–gene and gene-environment interactions. Bioinformatics. 2003;19:376–82.PubMedCrossRef

19.

Mazumder B, Seshadri V, Fox PL. Translational control by the 3′-UTR: the ends specify the means. Trends Biochem Sci. 2003;28:91–8.PubMedCrossRef

20.

Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem. 2006;99:392–401.PubMedCrossRef

21.

Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008;3:e2578.PubMedCrossRef

22.

Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 1998;17:383–90.PubMedCrossRef

23.

Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, et al. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol. 2006;24:1982–9.PubMedCrossRef

Title: Common Variants in IGF1 Pathway Genes and Clinical Outcomes After Radical Prostatectomy
Authors: Chi-Fen Chang, PhD
Jiunn-Bey Pao, MS
Chia-Cheng Yu, MD
Chao-Yuan Huang, MD, PhD
Shu-Pin Huang, MD, PhD
Ying-Pi Yang, MS
Chun-Nung Huang, MD, PhD
Ta-Yuan Chang, PhD
Bang-Jau You, PhD
Hong-Zin Lee, PhD
Tzyh-Chyuan Hour, PhD
Bo-Ying Bao, PhD
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 7/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-2884-y

At a glance: The STEP trials

Springer Medicine

Common Variants in IGF1 Pathway Genes and Clinical Outcomes After Radical Prostatectomy

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2013

Locoregional Lymphadenectomy in the Surgical Management of Anorectal Melanoma

Paratesticular Liposarcoma: Unusual Patterns of Recurrence and Importance of Margins

Long-Term Survival After Gastrectomy for Cancer in Randomized, Controlled Oncological Trials: Comparison between West and East

Hospital Variation in Failure to Rescue after Colorectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audit

Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence

Staging Stage IV Colorectal Cancer